Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician demandResults of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious he ...

New York, New York--(Newsfile Corp. - March 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Disc and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January 15, 202 ...

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2]. Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence [3]. - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased Disc Medicine securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2] - Investors are encouraged to join the prospective class action by contacting Rosen Law Firm for more information [2] Group 2: Regulatory Issues - On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine regarding its bitopertin program, stating that the new drug application could not be approved due to uncertainties requiring additional evidence [3] - Following the FDA's announcement, Disc Medicine's stock price experienced a significant decline of 22% on the same day [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their experience and recognition in the field [4] - The firm has achieved notable settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON Accessibility StatementSkip NavigationNEW YORK, March 20, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.So W ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public. So What: If you purchased Disc Medicine securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency. ...

New York, New York--(Newsfile Corp. - March 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws.On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting EPP, a rare genetic disorder characterized by extreme photosensitivity. A CRL indicates that ...

IRON Drops Up to 39% After FDA CRL for Bitopertin -- LEVI & KORSINSKY, LLP Investigates Accessibility StatementSkip NavigationDisc Medicine investors who lost money after the FDA issued a Complete Response Letter for bitopertin are encouraged to contact Levi & KorsinskyNEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Disc Medicine, Inc. (NASDAQ: IRON) regarding whether the company adequately communicated risks regarding its bitopertin program before the FDA's issuance of a Com ...